{"name":"Etablissement Français du Sang","slug":"etablissement-fran-ais-du-sang","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":3,"colorKey":"oncology","drugs":[{"name":"Additive solution","genericName":"Additive solution","slug":"additive-solution","indication":"Other","status":"marketed"},{"name":"Apheresis donation","genericName":"Apheresis donation","slug":"apheresis-donation","indication":"Other","status":"phase_1"},{"name":"Autologous plasma","genericName":"Autologous plasma","slug":"autologous-plasma","indication":"Other","status":"marketed"}]},{"name":"Hematology","slug":"hematology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"Pathogen reduction process","genericName":"Pathogen reduction process","slug":"pathogen-reduction-process","indication":"Pathogen reduction of blood components (red blood cells, platelets, plasma) for transfusion","status":"marketed"}]}],"pipeline":[{"name":"Additive solution","genericName":"Additive solution","slug":"additive-solution","phase":"marketed","mechanism":"Biologic","indications":[],"catalyst":""},{"name":"Pathogen reduction process","genericName":"Pathogen reduction process","slug":"pathogen-reduction-process","phase":"marketed","mechanism":"A pathogen reduction technology that inactivates viruses, bacteria, and other pathogens in blood products through chemical or physical treatment to improve transfusion safety.","indications":["Pathogen reduction of blood components (red blood cells, platelets, plasma) for transfusion"],"catalyst":""},{"name":"Apheresis donation","genericName":"Apheresis donation","slug":"apheresis-donation","phase":"phase_1","mechanism":"Biologic","indications":[],"catalyst":""},{"name":"Autologous plasma","genericName":"Autologous plasma","slug":"autologous-plasma","phase":"marketed","mechanism":"Biologic","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiyAFBVV95cUxNcHZzUl9STmVYVWF4ZUFTV3lOQkRkUnF0ZmNRMDVlei1jUXZObzdBN2VWZFNzNUZ0bG84TUxtTWNyVmZiakRlcHFCY1ViMUh2bjVHN2lPRW5RbkxOVEdVSjZSMktCUHpITXNDWm1leEhjNzVydkpId2oycXk5TTQzeHNoRHdsZmJaNTdRRnNoaTVNaTlEYjBCa2kyTWFqSHhHSUhCOV9ETXhfOFBQNlFHeU8yaDlhYjFXdlhxYnIzdndrV19yUjgtYg?oc=5","date":"2025-07-03","type":"pipeline","source":"20 Minutes","summary":"Des médicaments issus du sang seront en rupture jusqu’à mi-2026 - 20 Minutes","headline":"Des médicaments issus du sang seront en rupture jusqu’à mi-2026 - 20 Minutes","sentiment":"neutral"}],"patents":[],"drugCount":4,"phaseCounts":{"marketed":3,"phase_1":1},"enrichmentLevel":0,"visitCount":3,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}